Sharp drops in Heron Therapeutics and Supernus Pharmaceuticals have presented opportunities to make lemonade out of lemons.
The market may need some rest and consolidation, but that doesn't mean it will produce a lot of downside.
Shares of Replimune Group and Eyenovia have swung up and down in 2019 but should be on the rise next year.
Like Karuna, Sage Therapeutics and Intra-Cellular Therapies also deal in treatments in the mental health arena.
Shares of Stemline Therapeutics and Entercom Communications headed opposite directions last Friday after reporting results.
Karyopharm Therapeutics and Pieris Pharmaceuticals are climbing this week on positive news, while Supernus Pharmaceuticals takes a hit.
Heron Therapeutics and TG Therapeutics each gave investors reasons for cheer in the last few days.
These stocks are priced for total imperfection. That's just what you want.
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
BIIB also reported third quarter results Tuesday that easily beat the consensus both on the top and the bottom line.